Abstract

**Background:** Maintenance of therapeutic International Normalized Ratio (INR) in the community is generally poor. The supervised environment in long-term care facilities may represent a more ideal setting for warfarin therapy since laboratory monitoring, compliance, dose adjustment, and interacting medications can all be monitored and controlled. The objectives of this study were to determine how effectively warfarin was administered to a cohort of residents in long-term care facilities, to identify the proportion of residents prescribed warfarin-interacting drugs and to ascertain factors associated with poor INR control.

**Methods:** A chart review of 105 residents receiving warfarin therapy in five long-term care facilities in Hamilton, Ontario was performed. Data were collected on INR levels, warfarin prescribing and monitoring practices, and use of interacting medications.

**Results:** Over a 12 month period (28,555 resident-days, 78.2 resident years) 3065 INR values were available. Residents were within, below and above the therapeutic range 54%, 35% and 11% of the time, respectively. Seventy-nine percent of residents were prescribed at least one warfarin-interacting medication during the period in review. Residents receiving interacting medications spent less time in the therapeutic range (53.0% vs. 58.2%, OR = 0.93, 95% confidence interval 0.88 to 0.97, P = 0.002). Adequacy of anticoagulation varied significantly between physicians (time in therapeutic range 45.9 to 63.9%).

**Conclusion:** In this group of long-term care residents, warfarin control was suboptimal. Both prescriber and co-prescription of interacting medications were associated with poorer INR control. Future studies should seek strategies to improve prescriber skill and decrease use of interacting medications.
Background
Warfarin is frequently prescribed to the elderly; often for primary or secondary prevention of stroke in patients with atrial fibrillation [1] or to prevent recurrent venous thromboembolism (VTE) [2]. Residents of long-term care (LTC) facilities are particularly likely to receive warfarin given the high prevalence of atrial fibrillation [3,4] and incidence of VTE [5] in this older population.

Although good quality evidence suggests an optimal target International Normalized Ratio (INR) of 2.0–3.0 for these common indications [6-8], maintenance of therapeutic INR in the community is generally poor [9-11]. LTC facilities may represent ideal environments for warfarin therapy since laboratory monitoring, compliance, dose adjustment, and interacting medications can all be monitored and controlled.

Despite the frequency of warfarin use in LTC and the unique care environment, relatively few studies have examined how well warfarin therapy is provided to residents of LTC facilities. We sought to address this knowledge deficit by performing a retrospective chart review. Our objectives were to determine: (1) the percentage of time residents spent in the therapeutic international normalized ratio (INR) range, (2) the prevalence and incidence of prescription of warfarin-interacting drugs and (3) whether co-prescription of medications known to interact with warfarin was associated with the proportion of time in the therapeutic range.

Methods
Setting and patients
The study sample consisted of all residents at five LTC facilities in Hamilton, Ontario. The facilities had a total of 1144 residents (mean 229 residents). These facilities provide nursing care and residential facilities for individuals no longer able to live in the community; each facility provides medication dispensing and laboratory monitoring services in addition to assistance with activities of daily living. All prescription medications received by residents are dispensed by a single pharmacy providing service to that facility.

Study design
Residents were identified from the centralized pharmacy database for the LTC facilities. The retrospective chart review included data from the preceding twelve months. Using a standardized form, two reviewers (MV and BM) abstracted data from facility charts for each resident receiving warfarin for the period between October 2004 and April 2005. Information collected included: indication for anticoagulation, INR results, target range, and INR-testing intervals. In addition demographic data for each participant, including age, sex, comorbidities, concomitant medications and prescribing physician was recorded for statistical analysis.

To identify prescription of medications known to interact with warfarin, we compiled a list based on “highly probable” and “probable” interactions in a recent systematic review, [12] and cross-referenced it with the pharmacy database for our sample population. Initiation or change in dose of medications known to interact with warfarin was also recorded.

Statistical analysis
Analysis of quantitative (including descriptive statistics) and qualitative data was conducted. In the primary analysis we assessed quality of treatment based on TTR (therapeutic range = 2.0–3.0). Linear interpolation of INR, in the method of Rosendaal et al. [13], was used to characterize each day of warfarin therapy: INR values were assigned to each day between INR measurements based on a postulated linear change. Values were rounded to one decimal place. Mantel-Haenszel weighted odds ratios (OR's) and 95% CI's were computed where appropriate (EpiInfo, Centers for Disease Control, Atlanta, Georgia, 2004). The association between baseline and time dependent factors and adequacy of anticoagulation was to be queried using univariable analysis. Multivariable analysis proved not to be possible because of strong interaction between baseline and time dependent variables.

Ethics
Before proceeding with data collection, approval was obtained from the Medical Director, Administrator, and Director of Care at each facility. Consent was not obtained from individual residents. Each resident was assigned a numerical code which was used on all study documents to prevent identification of their personal information. The facility’s Professional Advisory Committee reviewed the protocol. Approval for this project was received from the Research Ethics Board at McMaster University.

Results
Sample demographics
Overall, 107 of 1144 (9%, 95% CI 8% to 11%) residents were prescribed warfarin. Residents prescribed warfarin were predominantly female (72%), with a mean age of 83.6 years (range 54.7–98.0). All but two of the residents were over the age of 65. Two residents had medical indications for target INR above 2.0–3.0 and were thus excluded from the analysis. Depending on length of stay at the LTC facilities and duration of anticoagulation with warfarin, the duration of the audit for individual residents ranged from 0.7 to 13.3 months (mean 9.1).

The majority of residents in our sample had atrial fibrillation (67%), or a history of stroke or transient ischemic
A large proportion had hypertension (50%), coronary artery disease (48%), dementia (37%), osteoarthritis (31%), congestive heart failure (31%) or diabetes mellitus (22%). The percentage of residents with depression, chronic obstructive pulmonary disease, osteoporosis, asthma, anemia, renal impairment and history of cancer was 18%, 14%, 14%, 10%, 8%, 6% and 20% respectively. The most common indications for warfarin were stroke prophylaxis in atrial fibrillation (67%) and treatment of deep vein thrombosis (18%) (Figure 1). In 9 of the 105 residents (9%) the indication for anticoagulation with warfarin was not clear after complete review of the facility chart, though the stated target INR was 2.0–3.0. Ten residents had two documented indications for warfarin therapy.

**INR**

Over the period of the chart review, a total of 3065 INR values were available, representing 28,555 resident days (78.2 resident years). The average number of INR measurements per resident was 3.4 per month (average of one measurement every 9 days). Linear interpolation of INR values [13] was performed to assign an INR value to each patient day. Overall, residents spent 54.1% of time in the therapeutic range (INR 2.0–3.0). Residents’ anticoagulation was subtherapeutic (<2.0) 34.7% of the time and supratherapeutic (>3.0) 11.2% of the time. We further broke down the data into ranges and found that a large proportion of the time (27.7%) was spent in the INR range of 1.6–1.9 (Figure 2).

**Interacting medications**

Overall, 79% of residents on warfarin therapy (83 residents) were prescribed at least one interacting drug during the period of the chart review (mean no. interacting medications = 1.8, range 1–6). The five most common drugs were acetaminophen, citalopram, acetylsalicylic acid, diltiazem and simvastatin (Table 1). To examine monitoring practices, we further determined whether addition or dose change of drugs known to interact with warfarin was followed by INR measurement within seven days. There were 72 instances of newly-initiated warfarin-interacting medications or changes in dose. In 59 of 72 instances (82%) the INR was checked within 7 days of the initiation of the medication.

Residents receiving warfarin-interacting medications during the period of the chart audit had a TTR of 53.0%, compared with a TTR of 58.2% in the residents on no interacting drugs (OR = 0.93, 95% CI, 0.88 to 0.97, P = 0.002). Residents with 2 or more interacting medications had a lower TTR (50.8%) than those with only one interacting medication (55.1%) (Table 2a).

**Prescribing physicians**

Twenty individual physicians were identified as warfarin prescribers at the five facilities (prescribers-per-facility range, 2–10). To increase the reliability of our observations, TTR was determined for only the ten physicians with (1) three or more patients receiving warfarin and (2) total patient-INR-days ≥ 700. We found significant differences in the achieved TTR between the physicians (range...
Discussion
This study is the first to assess TTR in LTC residents on warfarin in Canada. We found that the quality of anticoagulant care was sub-optimal; overall, INR was in the therapeutic range 54% of the time and was subtherapeutic 35% of the time. The majority of residents received at least one warfarin-interacting drug. Eighty-two percent of times an interacting drug was started, INR testing occurred within one week, which compares favorably to monitoring in a study in outpatients (INR testing within 14 days, 77% of the time) [14]. Despite monitoring, TTR was lower in residents receiving warfarin-interacting medications. The quality of anticoagulation also varied significantly between physicians (TTR 45.9 to 63.3%).

The overall TTR result we obtained is comparable with that reported in three previous studies (TTR range 40 to 51%) [15-17]. However, the values compare unfavorably with an average TTR of 61% in studies in outpatients receiving warfarin. [6]

The finding that patients in LTC facilities have suboptimal INR control is surprising given the fact that many conditions which predict poor control in the community (in particular lack of compliance, failure to account for interacting medications, and failure to undergo monitoring) should be controlled in LTC. In fact each of these variables was controlled in our study; patient compliance was assured by central medication dispensing, monitored administration and frequent monitoring [18,19]. In addition to frequent use of interacting drugs in a LTC setting, other barriers to optimal INR control may include frequent staff shift changes, communication failures regarding dose adjustment and resident mental health issues.

Our study has several limitations including a limited sample size. The chart audit design did not allow us to track the possible combined effect of interacting medications and warfarin doses on INR results, limited our ability to explore additional factors that may have contributed to sub-optimal INR such as acute co-morbidities and variability in dietary vitamin K intake and also prevented multivariable analysis. In addition, we did not verify administration of individual warfarin doses. Despite this our results are important as we used rigorous methods to review, in duplicate, clinical charts from a well characterized cohort of patients from a LTC facility. We carefully calculated the TTR, and used rigorous statistical methodology to explore factors that may have contributed to inadequate anticoagulant control.

Conclusion
Our study provides preliminary evidence of the high prevalence of co-prescription of warfarin and interacting medications in LTC and the correlation with poorer INR control. The area of co-prescription of warfarin and interacting drugs has been inadequately studied – in the community and in LTC – and, to our knowledge, this study represents the first study of its kind. As suggested by a recent study in ambulatory care [20], a combined approach of physician education and automated alerts may be useful in decreasing co-prescription of interacting drugs. If a warfarin-interacting drug was medically necessary for a patient receiving oral anticoagulation, this approach, combined with pharmacy monitoring, would encourage prompt post-prescription INR monitoring.

Table 1: Prevalence of interacting medications. Number (percentage) of residents prescribed each warfarin-interacting medication over the period of the chart audit.

| Medication              | No. of Residents Prescribed (%) |
|-------------------------|---------------------------------|
| Acetaminophen           | 42 (40%)                        |
| Citalopram              | 26 (25%)                        |
| Acetylsalicylic acid    | 17 (16%)                        |
| Diltiazem               | 12 (11%)                        |
| Simvastatin             | 10 (10%)                        |
| Levofoxacin             | 8 (8%)                          |
| Phenytoin               | 7 (7%)                          |
| Ciprofl oxacin          | 5 (5%)                          |
| Sertaline               | 5 (5%)                          |
| Cotrimoxazole           | 3 (3%)                          |
| Metronidazole           | 3 (3%)                          |
| Clarithromycin          | 3 (3%)                          |
| Amiodarone              | 3 (3%)                          |
| Amoxicillin-clavulanate | 2 (2%)                          |
| Miconazole              | 1 (1%)                          |
| Propranolol             | 1 (1%)                          |
| Fluvoxamine             | 1 (1%)                          |

Medications not prescribed: erythromycin, fluconazole, fluvastatin, quinidine, ropinerole, celecoxib and entacapone.
Our study was implemented after completion of a learning needs-assessment with the medical directors of the five facilities. The results presented here have been shared with all the directors of care who support a planned future study assessing methods to improve TTR and drug-INR monitoring in long-term care. This trial will compare a previously validated decision-support tool [21] and automated interactions alerts with traditional physician management after academic detailing by a pharmacist on appropriate target INR and interaction management. Future studies should examine several variables simultaneously to determine which are most predictive of improved TTR.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MV and BM contributed to concept and design of study; data gathering, analysis and interpretation; and preparation of article for submission. MAC, CK, LD, GC, LW and AP contributed to concept and design of study; data analysis and interpretation; and preparation of the manuscript for submission. All authors read and approved the final manuscript.

Acknowledgements
Funding from the Canadian Institute of Health research supported the environmental scan of prescribing issues in LTC and knowledge translation. A research scholarship from the Regional Medical Associates provided funds for technical support. Neither agency was involved in any of the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript.

Dr Crowther is a Career Investigator of the Heart and Stroke Foundation of Ontario.

References
1. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA: Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998, 352:1167-1171.
2. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE: Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004, 164:2260-2265.
3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Wittenman JC: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006, 27:949-955.
4. Aronow WS, Ahn C, Gutstein H: Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci 2002, 57:M45-M46.
5. Heit JA, Melton LJ III, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, O’Fallon WM: Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001, 76:1102-1110.
6. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Celli C, Nalysnyk L: Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004, 126:1938-1945.
7. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Foggie M, Green D, Costantini L, Yscura W, Wilson S, Gent M, Kovacs MJ: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.
8. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger

Table 2: TTR calculated for variables of a) interacting medications and b) prescribing physician

| Warfarin-Interacting Medications? | Number of Interacting Meds | Number of INR-Days | Days in Therapeutic Range (INR 2.0–3.0) | TTR (%) |
|----------------------------------|---------------------------|--------------------|----------------------------------------|---------|
| Yes                              | Overall                   | 22683              | 12028                                  | 53.0    |
|                                  | 3+                        | 4328               | 2199                                   | 50.8    |
|                                  | 2                         | 6608               | 3357                                   | 50.8    |
|                                  | 1                         | 11747              | 6472                                   | 55.1    |
| No                               | None                      | 5872               | 3419                                   | 58.2    |

b)

| Physician ID# | Number of INR-Days | Days in Therapeutic Range (INR 2.0–3.0) | TTR (%) |
|---------------|--------------------|----------------------------------------|---------|
| 1             | 2150               | 1360                                   | 63.3    |
| 2             | 3137               | 1967                                   | 62.7    |
| 3             | 1468               | 916                                    | 62.4    |
| 4             | 2310               | 1396                                   | 60.4    |
| 5             | 1083               | 619                                    | 57.2    |
| 6             | 3334               | 1823                                   | 54.7    |
| 7             | 971                | 474                                    | 48.8    |
| 8             | 6144               | 2961                                   | 48.2    |
| 9             | 700                | 337                                    | 48.1    |
| 10            | 4383               | 2011                                   | 45.9    |
M, Hambleton J, Gent M: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349:631-639.

9. Gottlieb LK, Salem-Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994, 154:1945-1953.

10. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgeski AE: Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002, 113:42-51.

11. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J: Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000, 160:967-973.

12. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.

13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.

14. Rabel MA, Witt DM, Carroll NM, Magid DJ: Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy. Pharmacotherapy 2005, 25:1055-1061.

15. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J: Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997, 157:978-984.

16. Gurwitz JH, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, DeBells K, Moldoff J, Verzien N: The safety of warfarin therapy in the nursing home setting. Am J Med 2007, 120:539-544.

17. McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, Radford MJ: Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001, 161:2458-2463.

18. Samsa GP, Matchar DB: Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000, 9:283-292.

19. Horskotte D, Piper C, Wiemer M: Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease. J Thromb Thrombolysis 1998, 5 Suppl 1:19-24.

20. Feldstein AC, Smith DH, Perrin N, Yang X, Simon SR, Krall M, Sitrig DF, Ditmer D, Platt R, Soumerai SB: Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med 2006, 166:1009-1015.

21. Wilson SE, Costantini L, Crowther MA: Paper-based dosing algorithms for maintenance of warfarin anticoagulation. J Thromb Thrombolysis 2007, 23:195-198.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2318/8/13/prepub